Teriflunomide NDC 62332-314

NDC codes

FDA NDC Directory

Product NDC (as listed)62332-314Labeler and product segments. Claims need a package NDC.

Product NDC at billing width62332-0314Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
62332-314-14	62332031414	2 BLISTER PACK in 1 CARTON (62332-314-14) / 14 TABLET, FILM COATED in 1 BLISTER PACKMarketed from Jan 25, 2023
62332-314-30	62332031430	30 TABLET, FILM COATED in 1 BOTTLE (62332-314-30)Marketed from Jan 25, 2023
62332-314-91	62332031491	1000 TABLET, FILM COATED in 1 BOTTLE (62332-314-91)Marketed from Jan 25, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Teriflunomide
Generic name (nonproprietary): teriflunomide
Active ingredients: Teriflunomide — 14 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Alembic Pharmaceuticals Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 209572
Marketing start: Jan 25, 2023
Listing expires: Dec 31, 2027
Other FDA classes: Dihydroorotate Dehydrogenase Inhibitors (Mechanism)
Identifiers: Product ID 62332-314_95e1ed70-9c5b-4bad-a26e-b33cd3f9b7eeSPL ID 95e1ed70-9c5b-4bad-a26e-b33cd3f9b7eeSPL set ID 8c1bc23b-a62b-4172-a603-8b97761514b4RxCUI 1310525, 1310533UNII 1C058IKG3BUPC 0362332313303, 0362332314300
Pharmacologic class: Pyrimidine Synthesis Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N462332031414 followed by a unit qualifier and the quantity

Package 62332-0314-14. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 17, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Teriflunomide tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Teriflunomide tablet is a pyrimidine synthesis inhibitor indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 209572

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 209572
Product	Strength	Form · route	Labeler	Product NDC
Teriflunomide	Teriflunomide 7 mg/1	Tablet, Film coatedOral	Alembic Pharmaceuticals Limited	46708-313
Teriflunomide	Teriflunomide 14 mg/1	Tablet, Film coatedOral	Alembic Pharmaceuticals Limited	46708-314
Teriflunomide	Teriflunomide 7 mg/1	Tablet, Film coatedOral	Alembic Pharmaceuticals Inc.	62332-313